文献速递食管与纵隔外科

新辅助免疫化疗后食管鳞癌的病理分类:区分术后结局并探索辅助治疗获益

A pathologic classification approach in esophageal squamous cell carcinoma following neoadjuvant immunochemotherapy: Distinguishing postoperative outcomes and exploring the potential benefit of adjuvant therapy.
PubMed 文献 · J Thorac Cardiovasc Surg · 2025-06-19

该研究回顾性纳入2019至2022年间接受新辅助免疫化疗后根治性食管切除术的局部晚期食管鳞癌患者333例,基于MPR与ypN状态建立病理分类。中位随访23.8个月,总体pCR率25.8%,1年和2年RFS率分别为77.0%和63.2%。ypN0患者预后良好;

要点

  • 基于MPR和ypN的病理分类可区分术后RFS和复发模式。
  • ypN0患者预后良好,ypN+患者中MPR与局部复发相关。
  • MPR且ypN+患者辅助治疗与RFS改善相关(HR 0.38)。

核心结论

  • 基于MPR-ypN的病理分类可区分术后结局,并提示MPR且ypN+患者可能从辅助治疗中获益。

研究设计与样本

  • 回顾性收集2019至2022年间接受新辅助免疫化疗后根治性食管切除术的局部晚期食管鳞癌患者数据,共纳入333例 eligible 患者。
  • 主要结局为无复发生存(RFS),次要结局包括复发模式、总生存、局部无复发生存和远处无转移生存。
  • 采用Kaplan-Meier法绘制生存曲线,倾向性评分匹配匹配不同组,Cox比例风险模型识别影响预后因素。

主要发现

  • 333例患者总体病理完全缓解(pCR)率为25.8%。
  • 中位随访23.8个月,1年和2年RFS率分别为77.0%和63.2%。
  • 多因素分析确定ypN是影响RFS的主要因素,ypN和MPR状态均为复发模式的关键决定因素。
  • ypN0患者预后良好;在ypN+患者中,MPR与更多局部区域复发相关,而非MPR病例主要表现为远处转移。

临床怎么用

  • 可依据MPR和ypN状态对术后患者进行风险分层,ypN0预后良好。
  • 对MPR且ypN+患者,可考虑辅助治疗以改善RFS。
  • ypN+且非MPR患者以远处转移为主,需关注远处转移监测。

局限性

  • 本研究为回顾性设计,可能存在选择偏倚。
  • 辅助治疗获益的结论基于亚组分析,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant immunochemotherapy has demonstrated promising efficacy in locally advanced esophageal squamous cell carcinoma (ESCC), yet the role of adjuvant therapy remains unclear. This study aimed to develop a pathologic classification scheme to distinguish postoperative outcomes and explore the potential benefit of adjuvant therapy. METHODS: This study retrospectively collected data on patients with locally advanced ESCC who underwent radical esophagectomy after neoadjuvant immunochemotherapy between 2019 and 2022. The primary outcome was recurrence-free survival (RFS), and secondary outcomes included recurrence patterns, overall survival, locoregional recurrence-free survival, and distant metastasis-free survival. The Kaplan-Meier method was used to plot survival curves, propensity score matching was used to match different groups, and Cox proportional hazards models identified factors affecting prognosis. RESULTS: Among 333 eligible patients, the overall pathologic complete response (pCR) rate was 25.8%. With a median follow-up of 23.8 months, the 1-year and 2-year RFS rates were 77.0% and 63.2%, respectively. Multivariable analysis identified ypN as the primary factor influencing RFS, while both ypN and MPR status were key determinants of recurrence patterns. A classification approach based on MPR and ypN status was developed to distinguish patient subgroups with different RFS and recurrence patterns. Patients with ypN0 had a favorable prognosis. In ypN+ patients, MPR was linked to more locoregional recurrences, while non-MPR cases showed mainly distant metastases. Among MPR ypN+ patients, adjuvant therapy was associated with improved RFS (hazard ratio, 0.38; 95% confidence interval, 0.15- 0.93; P = .028). CONCLUSIONS: The MPR-ypN-based classification distinguishes postoperative outcomes and suggests that MPR ypN+ patients may derive benefit from adjuvant therapy.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Lin L, Yang Y, Song X, et al. A pathologic classification approach in esophageal squamous cell carcinoma following neoadjuvant immunochemotherapy: Distinguishing postoperative outcomes and exploring the potential benefit of adjuvant therapy. J Thorac Cardiovasc Surg. 2025. PMID: 40543899. doi:10.1016/j.jtcvs.2025.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。